Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.64 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | ABL2 | P42684 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | ADK | P55263 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868363 | 0.89 | SRC (0.60) | SRCEGFRABL1ABL2ADK | |
| SCHEMBL19731287 | 0.88 | SRC (0.65) | SRCEGFRABL1ABL2MEN1 | |
| SCHEMBL14637043 | 0.88 | SRC (0.65) | SRCEGFRABL1ABL2FGFR1 | |
| SCHEMBL15913719 | 0.88 | SRC (0.65) | SRCEGFRABL1ABL2FGFR1 | |
| SCHEMBL357171 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2ADK | |
| SCHEMBL1444035 | 0.88 | SRC (0.64) | SRCEGFRABL1ABL2MEN1 | |
| SCHEMBL29503400 | 0.88 | SRC (0.64) | SRCEGFRABL1ABL2MEN1 | |
| SCHEMBL25235863 | 0.85 | ABL1 (0.61) | SRCEGFRABL1ABL2MEN1 | |
| SCHEMBL27889162 | 0.83 | JAK2 (0.48) | SRCEGFRABL1ABL2FGFR2 | |
| SCHEMBL28667953 | 0.83 | SRC (0.79) | SRCEGFRABL1ABL2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| CN-110627796-B | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-110627796-A | Nitrogenous heterocyclic derivative and application thereof in medicine | 北京越之康泰生物医药科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | SRC 2497/4885EGFR 49/4885ABL1 1021/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | SRC 2497/4885EGFR 49/4885ABL1 1021/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | SRC 1950/4885EGFR 2245/4885ABL1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.